Autres langues Phio Pharmaceuticals Corp.

Actions

PHIO

US71880W5013

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
1,030 ^USD	+1,98%		-4,63%	-1,90%

06/08	Phio Pharmaceuticals Corp. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
21/07	Phio Pharmaceuticals Corp. nomme R. Todd Plott à son conseil d'administration et au comité de gouvernance, avec effet au 20 juillet 2026	CI

Autres langues

11/09	Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
11/08	Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
07/08	Phio Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
06/08	Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
22/07	Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
22/07	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
21/07	Phio Pharmaceuticals Corp. Appoints R. Todd Plott to its Board and Governance Committee, Effective July 20, 2026
21/07	Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
15/07	Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
15/07	Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
26/06	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
25/06	Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
24/06	Phio Pharmaceuticals Corp. Announces the Manufacture of the First Commercial-Scale Cgmp Batch of Ph-762 Drug Substance Has Commenced At Nitto Denko Avecia, Inc
24/06	Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
18/06	Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
26/05	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
12/05	Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
08/05	Phio Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
23/04	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
13/04	Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
09/04	Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
08/04	Phio Pharmaceuticals Corp - Enters at the Market Offering Agreement with H.C. Wainwright on April 8, 2026